Paul Tudor Jones’s Catalyst Pharmaceutical CPRX Stock Holding History

Paul Tudor Jones’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,395	Closed	-$505K	–	3667
2026 Q1	$505K	Buy	+20,395	New	+$486K	﹤0.01%	2812
2025 Q3	–	Sell	-76,088	Closed	-$1.65M	–	3434
2025 Q2	$1.65M	Buy	76,088 +14,502	+24%	+$342K	﹤0.01%	1800
2025 Q1	$1.49M	Buy	61,586 +2,034	+3%	+$45.8K	0.01%	1547
2024 Q4	$1.24M	Buy	+59,552	New	+$1.28M	﹤0.01%	1574
2022 Q4	–	Sell	-73,965	Closed	-$949K	–	2461
2022 Q3	$949K	Buy	+73,965	New	+$877K	0.02%	946

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paul Tudor Jones's CPRX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 20,395 shares — an estimated $505K sold.

Paul Tudor Jones first reported a position in CPRX in Q3 2022 and held it in 5 quarters. The position peaked at $1.65M in Q2 2025. 392 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Paul Tudor Jones reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 20,395 Catalyst Pharmaceutical shares in Q2 2026, an estimated $505K.
Paul Tudor Jones first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 5 quarters.
Paul Tudor Jones's Catalyst Pharmaceutical position peaked at $1.65M in Q2 2025.
392 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.